Real-world data show most first-line mTNBC patients are immunotherapy-ineligible, use chemotherapy, and face poorer survival, underscoring major unmet treatment needs.
Bridgette Leclair
Advertisement
Articles by Bridgette Leclair
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
3
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
4
Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3
5